# A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism

> **NCT07646535** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Primary Aldosteronism

## Interventions

- **DRUG:** SAL0140 Tablets
- **DRUG:** SAL0140 Tablets
- **DRUG:** SAL0140 placebo

## Key facts

- **NCT ID:** NCT07646535
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-12
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07646535

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07646535, "A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Primary Aldosteronism". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07646535. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*